Goldman Sachs Group Inc 2seventy Bio, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSVT
# of Institutions
128Shares Held
45MCall Options Held
40.4KPut Options Held
4.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$15.1 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$9.55 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$9.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.92MShares$7.41 Million0.0% of portfolio
-
Newtyn Management, LLC New York, NY2.53MShares$6.44 Million1.51% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $96.2M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...